XOresearch is excited to announce a significant milestone in its journey towards revolutionizing cardiac care with the successful raise of $10 million for its flagship product, CardioAI. As a pioneering company focused on integrating deep learning technology into real-life applications, particularly in natural language processing and healthcare, XOresearch is dedicated to enhancing the efficiency and accuracy of patient monitoring. CardioAI, an innovative software medical device, utilizes advanced deep learning algorithms to autonomously annotate and interpret electrocardiograms (ECGs) recorded from any legally marketed source. This cutting-edge technology allows for unattended cardiac monitoring, streamlining the workflow with a seamless Electronic Health Record (EHR) interface.
The funding acquired will be instrumental in advancing CardioAI’s capabilities, allowing the company to enhance its real-time data processing features that currently enable the interpretation of 24-hour ECGs in just 30 seconds. This rapid analysis offers a valuable tool for healthcare providers, aiding in the management of chronic cardiac conditions while significantly reducing the need for non-essential hospitalizations. With its ability to integrate smoothly into existing healthcare systems and mobile devices, CardioAI empowers healthcare professionals to deliver timely and effective care, even in remote or challenging environments. As XOresearch continues to push the boundaries of healthcare technology, this funding will ensure that CardioAI reaches its full potential, ultimately improving health outcomes for patients worldwide.
